Congressman Robert Dold Meets With Marathon Pharmaceuticals to Discuss Advances in Medical Research and Development

Share Article

Rep. Robert Dold (Ill.-10) today met with employees at Marathon Pharmaceuticals to discuss their shared commitment to research and development that can bring new rare disease treatments to the patients who need them. Rep. Dold is dedicated to funding medical research that leads to new treatments and better quality of life for patients.

News Image
“Rep. Dold has long been a champion for medical research and innovation, and his efforts have helped the private sector bring hope to patients with unmet medical needs,” said Jeff Aronin, CEO of Marathon Pharmaceuticals.

Rep. Robert Dold (Ill.-10) today met with employees at Marathon Pharmaceuticals to discuss their shared commitment to research and development that can bring new rare disease treatments to the patients who need them.

Rep. Dold is dedicated to funding medical research that leads to new treatments and better quality of life for patients. Dold is a strong supporter of the 21st Century Cures Act, which was approved by the U.S. House this July. The 21st Century Cures Act aims to increase the number of drugs approved to treat rare diseases and provides a significant increase in funding for the National Institutes of Health (NIH).

“There are currently 10,000 known diseases, and sadly, we have cures for only 500,” Rep. Dold said. “There is no doubt that the United States has the best researchers and scientists in the world and the rigors and expense of drug development can delay approval of desperately needed new drugs. That’s one of the many reasons I have championed the bipartisan 21st Century Cures Act, which will increase funding for medical research and streamline regulatory processes. Together we can find new cures and change the lives of patients living with devastating diseases.”

Marathon is one of the pharmaceutical companies working to bring the promise of medical innovation to patients with unmet medical needs. Marathon works closely with researchers and patient advocates to develop new treatments for rare neurological and movement disorders. The company is developing a pipeline of rare disease treatments including a potential treatment for children with Duchenne muscular dystrophy.

“Rep. Dold has long been a champion for medical research and innovation, and his efforts have helped the private sector bring hope to patients with unmet medical needs,” said Jeff Aronin, CEO of Marathon Pharmaceuticals. “We were honored to be able to meet with Congressman Dold today and discuss how government and industry can work together to improve patients’ lives.”

About Marathon Pharmaceuticals
Marathon Pharmaceuticals, LLC is a biopharmaceutical company that develops new treatments for rare diseases with a focus on providing medicine to patients who currently have no treatment options. The company is developing a pipeline of treatments for rare neurological and movement disorders. Marathon is headquartered in Northbrook, Illinois, with offices in Chicago, New Jersey and Washington D.C. For more information, visit http://www.marathonpharma.com.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Peter Gray
Aileron Communications, Inc.
+1 (312) 629-9400
Email >

Media